2-[8-tert-butyl-6-[2-(5,6-diethoxy-4-fluoro-3-imino-1H-isoindol-2-yl)acetyl]-2,3-dihydro-1,4-benzoxazin-4-yl]acetonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 2-[8-tert-butyl-6-[2-(5,6-diethoxy-4-fluoro-3-imino-1H-isoindol-2-yl)acetyl]-2,3-dihydro-1,4-benzoxazin-4-yl]acetonitrile
• 化学式: C₂₈H₃₃FN₄O₄
• 分子量: 508.6
• InChiKey: YLOATXQHGRUERV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  98.9
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH NAR AGONISTS
  申请人：Perelman Michael Sidney

  公开号：US20110065676A1

  公开（公告）日：2011-03-17

  The present invention is directed to a pharmaceutical composition comprising an effective amount of at least one PAR1 antagonist, at least one NAR agonist, optionally, an effective amount of at least one cardiovascular agent, and, optionally, a pharmaceutically acceptable carrier. The present invention also provides for the use of theses pharmaceutical compositions to treat various diseases associated with thrombosis.
• US7244730B2
  申请人：——

  公开号：US7244730B2

  公开（公告）日：2007-07-17
• [EN] COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH PAR4 ANTAGONISTS<br/>[FR] THÉRAPIES DE COMBINAISON COMPRENANT DES ANTAGONISTES DE RÉCEPTEUR 1 ACTIVÉ PAR PROTÉASE (PAR1) ASSOCIÉS À DES ANTAGONISTES RÉCEPTEUR 4 ACTIVÉ PAR PROTÉASE (PAR4)
  申请人：SCHERING CORP

  公开号：WO2009124103A2

  公开（公告）日：2009-10-08

  The present invention is directed to a pharmaceutical composition comprising an effective amount of at least one PAR1 antagonist, at least one PAR4 antagonist, optionally, an effective amount of at least one cardiovascular agent, and, optionally, a pharmaceutically acceptable carrier. The present invention also provides for the use of theses pharmaceutical compositions to treat various diseases associated with thrombosis.